Te­va sees room for growth with FDA com­mu­ni­ca­tions and com­plex gener­ics, COO says

While em­broiled in le­gal bat­tles, gener­ic drug gi­ant Te­va Phar­ma­ceu­ti­cals is hop­ing to turn a cor­ner with the FDA in im­prov­ing their com­mu­ni­ca­tions and fo­cus on com­plex gener­ics.

“The con­cern we have as an in­dus­try as we move in­to a new era of sci­ence where a lot of the prod­ucts that are com­ing off patent are more com­pli­cat­ed and fall in­to this sort of com­plex gener­ics cat­e­go­ry — we think it’s up to a third of the [gener­ic] prod­ucts al­to­geth­er — we need to fig­ure out how to get those prod­ucts to mar­ket,” Chris­tine Baed­er, SVP and chief op­er­at­ing of­fi­cer at Te­va, told End­points News in a phone in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER